CliffBio
biologic

Briumvi

ublituximab-xiiy

Loss of exclusivityDecember 2034projected — 12-year biologic exclusivity estimate
CompanyTg Therapeutics, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameBriumvi
Active ingredientublituximab-xiiy
Strength150MG/6ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2022
Marketing statusRx

More from Tg Therapeutics, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Briumvi patent cliff — loss of exclusivity December 2034 | CliffBio